MDT / Medtronic plc - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 25, 2025 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 25, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

Medtronic reports first quarter fiscal 2026 financial results 11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2026 financial results 11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland – August 19, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), wh

Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating commi

Exhibit 99.2 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Medtronic plc (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the gaurantor of the stated securities from listing and registration on the Exchange at the opening of business on July 14, 2025, pursuant to the provisions of Rule 12d2-2 (a).

Medtronic Board appoints Dr. Joon Lee as a new director

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Dr.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

Medtronic plc Global Insider Trading Policy

Exhibit 19 Global Insider Trading Policy Purpose The U.S. Securities and Exchange Commission (SEC) and other government bodies created rules to prevent unethical use of nonpublic information. This policy outlines the requirements employees must follow to comply with these rules and applicable laws. Scope This policy applies to all Medtronic employees and members of the Board of Directors. Policy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 25, 2025. ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 25, 2025. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ® Medtronic plc (Exact name of reg

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 25, 2025 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Medtronic Nonqualified Retirement Plan Supplement

2025 MEDTRONIC NONQUALIFIED RETIREMENT PLAN SUPPLEMENT (as amended and restated effective March 3, 2025) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT Section 1.

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

Medtronic plc Policy For The Recovery of Erroneously Awarded Compensation

Exhibit 97 MEDTRONIC PLC POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Description Medtronic plc, an Irish public limited company (the “Company”) has adopted this Policy for the Recovery of Erroneously Awarded Compensation (the “Policy”), pursuant to the requirements of the New York Stock Exchange listing standards and Exchange Act Rule 10D-1.

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

Description of Registrant's Securities

Exhibit 4.30 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of Medtronic plc, a company incorporated under the laws of Ireland (“Medtronic” or “Medtronic plc”), (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 3.000% Se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Building Two, Parkmore Business Park West Galway, Ireland n/a (Address of principal exec

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2024 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2024 to December 31, 2024 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuro

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland – May 21, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare t

Medtronic announces intent to separate Diabetes business Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; o

Exhibit 99.2 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic announces intent to separate Diabetes business Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland – May 21

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

Letter Agreement by and between Medtronic, Inc. and Thierry Piéton dated December 24, 2024

Medtronic, Inc. 710 Medtronic Parkway, LC210 Minneapolis, MN 55432-5604 USA Tel: 1.763.514.4000 www.medtronic.com December 24, 2024 Mr. Thierry Pieton Dear Thierry, I am pleased to provide you with this offer of employment at Medtronic. Your valuable experience will help shape our business and improve the lives of patients. Building the right team of talented people plus our market-leading positio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 24, 2025 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 24, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports third quarter fiscal 2025 financial results Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2025 financial results Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland – Feb. 18,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

Medtronic appoints Thierry Piéton as Chief Financial Officer

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic appoints Thierry Piéton as Chief Financial Officer GALWAY, Ireland – Date – Jan.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 25, 2024 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 25, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports second quarter fiscal 2025 financial results Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spin

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2025 financial results Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabet

Medtronic plc

Medtronic plc Building Two Parkmore Business Park West Galway, Ireland www.medtronic.com November 18, 2024 Via EDGAR Correspondence Mr. Michael Fay United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Mail Stop 3030 Washington, DC 20549 Re: Medtronic plc Form 10-K for the Fiscal Year Ended April 26, 2024 Filed June 20, 2024 File No. 001-36820 Dear Mr. Fay

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 26, 2024 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 26, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports first quarter fiscal 2025 financial results Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pai

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2025 financial results Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 Medtronic plc (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

Medtronic announces departure of Karen Parkhill, Chief Financial Officer

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic announces departure of Karen Parkhill, Chief Financial Officer DUBLIN, June 26, 2024 - / PRNewswire / - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and chief financial officer to accept the role of chief financial officer for HP Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 26, 2024. ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 26, 2024. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ® Medtronic plc (Exact name of reg

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

Medtronic plc Global Insider Trading Policy

Exhibit 19 Global Insider Trading Policy Purpose The U.S. Securities and Exchange Commission (SEC) and other government bodies created rules to prevent unethical use of nonpublic information. This policy outlines the requirements employees must follow to comply with these rules and applicable laws. Scope This policy applies to all Medtronic employees and members of the Board of Directors. Policy S

Medtronic plc Policy For The Recovery of Erroneously Awarded Compensation

Exhibit 97 MEDTRONIC PLC POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Description Medtronic plc, an Irish public limited company (the “Company”) has adopted this Policy for the Recovery of Erroneously Awarded Compensation (the “Policy”), pursuant to the requirements of the New York Stock Exchange listing standards and Exchange Act Rule 10D-1.

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 26, 2024 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

Description of Registrant's Securities

Exhibit 4.30 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of Medtronic plc, a company incorporated under the laws of Ireland (“Medtronic” or “Medtronic plc”), (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 3.000% Se

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic, Inc. (Exact name of registrant as

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic, Inc. (Exact name of registrant as specified in its charter) Minnesota 41-0793183 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N

Fifth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of June 3, 2024, among Medtronic, Inc., Medtronic plc, Medtronic Global Holdings S.C.A., Computershare Trust Company, N.A., as trustee, and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit 4.1 to Medtronic plc’s Form 8-K, filed on June 3, 2024)

EX-4.1 Exhibit 4.1 MEDTRONIC, INC. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC GLOBAL HOLDINGS S.C.A. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee, and ELAVON FINANCIAL SERVICES DAC, UK BRANCH, as Paying Agent FIFTH SUPPLEMENTAL INDENTURE Dated as of June 3, 2024 TO THE INDENTURE Dated as of December 10, 2014 Rela

Consent of Thomas L. Osteraas, Legal Director - Corporate & Securities of Medtronic, Inc. (included in Exhibit 5.4).

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com June 3, 2024 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic, Inc Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic, Inc., a Minnesota corporation (the “Company”) of €850,000,000 aggregate principal amount of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Underwriting Agreement, dated as of May 29, 2024, among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., and Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc, as representatives of the several underwriters named therein.

EX-1.1 Exhibit 1.1 EXECUTION VERSION UNDERWRITING AGREEMENT €3,000,000,000 MEDTRONIC, INC. 3.650% Senior Notes due 2029 3.875% Senior Notes due 2036 4.150% Senior Notes due 2043 4.150% Senior Notes due 2053 Underwriting Agreement May 29, 2024 Citigroup Global Markets Limited J.P. Morgan Securities plc Merrill Lynch International Mizuho International plc c/o Citigroup Global Markets Limited Citigro

Opinion of CM Law, Luxembourg counsel to Medtronic Global Holdings S.C.A.

EX-5.3 Exhibit 5.3   To: Medtronic Global Holdings S.C.A. 40, avenue Monterey, L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 3 June 2024 Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic Global Holdings GP S.à r.l. Dear Sirs, I. Introduction We have been appointed as legal counsel in the Grand Duchy of Luxembourg (“Luxembourg”) in order to prov

Agency Agreement, dated as of June 3, 2024, between Medtronic, Inc., Computershare Trust Company, N.A., as trustee, Elavon Financial Services DAC, UK Branch, as paying agent, and U.S. Bank National Association, as transfer agent and registrar

EX-4.6 Exhibit 4.6 DATED JUNE 3, 2024 ISSUER MEDTRONIC, INC. PAYING AGENT ELAVON FINANCIAL SERVICES DAC, UK BRANCH TRANSFER AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. REGISTRAR U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. - AND - TRUSTEE COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT relating to certain Notes issued under a supplemental indenture dated June 3, 2024

€3,000,000,000 MEDTRONIC, INC. €850,000,000 3.650% Senior Notes due 2029 €850,000,000 3.875% Senior Notes due 2036 €600,000,000 4.150% Senior Notes due 2043 €700,000,000 4.150% Senior Notes due 2053 Fully and Unconditionally Guaranteed by MEDTRONIC P

Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-270272-01 PROSPECTUS SUPPLEMENT (To Prospectus dated March 3, 2023) €3,000,000,000 MEDTRONIC, INC. €850,000,000 3.650% Senior Notes due 2029 €850,000,000 3.875% Senior Notes due 2036 €600,000,000 4.150% Senior Notes due 2043 €700,000,000 4.150% Senior Notes due 2053 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC

Calculation of Filing Fee Tables (Form Type) MEDTRONIC, INC. MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC GLOBAL HOLDINGS S.C.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: MEDTRONIC, INC.

Subject to Completion, dated May 29, 2024

Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-270272-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is

Medtronic, Inc. Pricing Term Sheet May 29, 2024 Issuer: Medtronic, Inc. Guarantors: Medtronic plc and Medtronic Global Holdings S.C.A. Trade Date: May 29, 2024 Settlement Date*: T+3; June 3, 2024 Denominations: €100,000 x €1,000 Listing: Issuer inten

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-270272-01 May 29, 2024 Medtronic, Inc. Pricing Term Sheet May 29, 2024 Issuer: Medtronic, Inc. Guarantors: Medtronic plc and Medtronic Global Holdings S.C.A. Trade Date: May 29, 2024 Settlement Date*: T+3; June 3, 2024 Denominations: €100,000 x €1,000 Listing: Issuer intends to apply to list the Notes on the New York

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2023 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2023 to December 31, 2023 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of principal executive of

Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Hear

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 26, 2024 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 26, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports third quarter fiscal 2024 financial results Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S.

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2024 financial results Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

OBIO / Orchestra BioMed Holdings, Inc. / Medtronic plc - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 mdt20240213sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Orchestra BioMed Holdings, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 68572M106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)

MDT / Medtronic plc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01437-medtronicplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Medtronic PLC Title of Class of Securities: Common Stock CUSIP Number: G5960L103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rul

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Medtronic plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate (1) Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration fee Equity Ordinary Shares, par v

As filed with the Securities and Exchange Commission on December 8, 2023

As filed with the Securities and Exchange Commission on December 8, 2023 Registration No.

Power of

Exhibit 24.1 POWER OF ATTORNEY RELATING TO REGISTRATION STATEMENT ON FORM S-8 FOR MEDTRONIC PLC 2024 EMPLOYEE STOCK PURCHASE PLAN We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Ivan K. Fong and Courtney Nelson Wills, and each of them singly, with full and several power of substitution and resubstitution and to act with or without the others, fo

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 27, 2023 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 27, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports second quarter fiscal 2024 financial results Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal ye

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2024 financial results Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

Medtronic plc 2024 Employee Stock Purchase Plan

MEDTRONIC PLC 2024 EMPLOYEE STOCK PURCHASE PLAN 1.Purpose of Plan. Medtronic plc (hereinafter referred to as the “Company”) proposes to grant to Employees of the Company and of certain of its Subsidiaries the opportunity to purchase ordinary shares of the Company. Such ordinary shares shall be purchased pursuant to this Plan, which is the MEDTRONIC PLC 2024 EMPLOYEE STOCK PURCHASE PLAN (hereinafte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 28, 2023 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 28, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan

MEDTRONIC plc RESTRICTED STOCK UNIT AWARD AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Shares Awarded: 1.

Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan

MEDTRONIC plc RESTRICTED STOCK UNIT AWARD AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Shares Awarded: 1.

Performance Share

MEDTRONIC plc PERFORMANCE SHARE UNIT AWARD AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Target PERFORMANCE SHARE UNITS: Performance Period: FY2023 to FY2025 (“Performance Period”) 1.

ualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan

MEDTRONIC plc NON-QUALIFIED STOCK OPTION AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Shares Awarded: Expiration Date: 1.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

Medtronic reports first quarter fiscal 2024 financial results Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2024 financial results Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals DUBLIN – Aug. 22,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

Medtronic Board appoints Greg Lewis as new Director

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Greg Lewis as new Director DUBLIN, June 26, 2023 - Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board.

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 28, 2023 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 28, 2023. ☐ Transition report pursuant to Sectio

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 28, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ® Medtronic plc

Amendment No. 2 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2020

AMENDMENT NO. 2 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 12, 2020 AMENDMENT NO. 2 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) among MEDTRONIC GLOBAL HOLDINGS S.C.A., a partnership limited by shares (société en commandite par actions) incorporated under the laws of the Grand-Duchy of Luxembourg having its r

Medtronic Nonqualified Retirement Plan Supplement dated as of April 28, 2023

MEDTRONIC NONQUALIFIED RETIREMENT PLAN SUPPLEMENT (as amended and restated effective April 28, 2023) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT.

Description of Registrant's Securities

Exhibit 4.25 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of Medtronic plc, a company incorporated under the laws of Ireland (“Medtronic” or “Medtronic plc”), and (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 1.625

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2022 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2022 to December 31, 2022 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company DUBLIN – May 25, 2023 –

Underwriting Agreement, dated as of March 23, 2023, among Medtronic Global Holdings S.C.A., Medtronic plc and Medtronic, Inc., and Barclays Capital Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein.

EX-1.1 Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT $2,000,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. 4.250% Senior Notes due 2028 4.500% Senior Notes due 2033 Underwriting Agreement March 23, 2023 Barclays Capital Inc. J.P. Morgan Securities LLC Mizuho Securities USA LLC c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o J.P. Morgan Securities LLC 383 Madison Avenue N

Seventh Supplemental Indenture, dated as of March 30, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (including the forms of the 2028 Notes and the 2033 Notes).

EX-4.2 Exhibit 4.2 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee SEVENTH SUPPLEMENTAL INDENTURE DATED AS OF MARCH 30, 2023 TO INDENTURE DATED AS OF MARCH 28, 2017 Relating to $1,000,000,000 4.250% Senior Notes due 2028 $1,000,000,000

Consent of Thomas L. Osteraas, Legal Director - Corporate and Securities of Medtronic, Inc. (included in Exhibit 5.4).

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com March 30, 2023 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic Global Holdings S.C.A. Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic Global Holdings S.C.A, an entity organized under the laws of Luxembourg (

Opinion of DLA Piper, Luxembourg counsel to Medtronic Global Holdings S.C.A.

EX-5.3 Exhibit 5.3 DLA Piper Luxembourg 37A, Avenue John F. Kennedy L-1855 Luxembourg T +352 26 29 04 2052 F +352 26 29 04 3000 W www.dlapiper.com Medtronic Global Holdings S.C.A. Our reference 40, avenue Monterey LM/CN/410009/1 L-2163 Luxembourg Grand Duchy of Luxembourg (“Addressee” or “you”) March 30, 2023 By Courier and E-mail Dear Sir, Dear Madam, 1. ROLE OF DLA PIPER LUXEMBOURG 1.1 DLA Piper

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Medtronic plc (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

$2,000,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. $1,000,000,000 4.250% Senior Notes due 2028 $1,000,000,000 4.500% Senior Notes due 2033 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC.

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-270272 PROSPECTUS SUPPLEMENT (To Prospectus dated March 3, 2023) $2,000,000,000 ® MEDTRONIC GLOBAL HOLDINGS S.C.A. $1,000,000,000 4.250% Senior Notes due 2028 $1,000,000,000 4.500% Senior Notes due 2033 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. Medtronic Global Hold

Calculation of Filing Fee Tables (Form Type) MEDTRONIC GLOBAL HOLDINGS S.C.A. MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: MEDTRONIC GLOBAL HOLDINGS S.

Medtronic Global Holdings S.C.A. Pricing Term Sheet March 23, 2023 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: March 23, 2023 Settlement Date*: T+5; March 30, 2023 Denominations: $2,000 x $1,000

FWP 1 d460820dfwp.htm FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-270272 March 23, 2023 Medtronic Global Holdings S.C.A. Pricing Term Sheet March 23, 2023 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: March 23, 2023 Settlement Date*: T+5; March 30, 2023 Denominations: $2,000 x $1,000 Expected Ratings (Mo

Subject to Completion, dated March 23, 2023

424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-270272 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the stated securities from listing and registration on the Exchange at the opening of business on March 27, 2023, pursuant to the provisions of Rule 12d2-2 (a).

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the entire class of the stated securities from listing and registration on the Exchange at the opening of business on March 21, 2023, pursuant to the provisions of Rule 12d2-2 (a).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

Form of Subordinated Indenture of Medtronic Global Holdings S.C.A. (including form of Note and Guarantee)

EX-4.4 Exhibit 4.4 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer and MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors TO , as Trustee SUBORDINATED INDENTURE Dated as of TABLE OF CONTENTS* Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 10 Section 1.03 Form of Documents Delivered to

Medtronic plc Powers of Attorney

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Ivan Fong and Martha Ha, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-3 filed herewith

Opinion of DLA Piper Luxembourg S.à r.l., Luxembourg counsel to Medtronic Global Holdings S.C.A. and Medtronic Global Holdings GP S.à r.l.

EX-5.3 Exhibit 5.3 Medtronic Global Holdings S.C.A. 40, avenue Monterey L-2163 Luxembourg Grand Duchy of Luxembourg in its capacity as Issuer (as defined below) Your reference Our reference LM/CN LU/410009/53 (“Addressee” or “you”) March 3, 2023 By Courier and E-mail Dear Sirs, REGISTRATION-FILING TO THE U.S. SECURITIES AND EXCHANGE COMMISSION – MEDTRONIC GLOBAL HOLDINGS S.C.A. 1. ROLE OF DLA PIPE

Sixth Supplemental Indenture, dated as of February 22, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (incorporated by reference to Exhibit 4.2 to Medtronic plc’s Registration Statement on Form S-3, filed on March 3, 2023, File No. 333-270272).

EX-4.2 Exhibit 4.2 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors, and COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee SIXTH SUPPLEMENTAL INDENTURE DATED AS OF FEBRUARY 22, 2023 TO INDENTURE DATED AS OF MARCH 28, 2017 SIXTH SUPPLEMENTAL INDENTURE, dated as of February 22, 2023 (the

As filed with the Securities and Exchange Commission on March 3, 2023

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 3, 2023 Registration No.

Consent of Thomas L. Osteraas, Legal Director – Corporate and Securities of Medtronic, Inc. (included in Exhibit 5.4)

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com March 3, 2023 Re: Registration Statement on Form S-3 Ladies and Gentlemen: This opinion is furnished to you in connection with a Registration Statement on Form S-3 (the “Registration Statement”) filed by Medtronic, Inc., a Minnesota corporation (the “Company”), Medtronic Public Limited Company, a public

The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the Trustee under the Medtronic, Inc. Senior Indenture

EX-25.3 Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the Trustee under the Senior Indenture of Medtronic Global Holdings S.C.A.

EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MEDTRONIC PUBLIC LIMITED COMPANY (Exact Name of Registrant as Specified in its Charter) MEDTRONIC GLOBAL HOLDINGS S.

Fourth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of February 22, 2023 among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as trustee

EX-4.9 Exhibit 4.9 MEDTRONIC INC. and COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee FOURTH SUPPLEMENTAL INDENTURE DATED AS OF FEBRUARY 22, 2023 TO INDENTURE DATED AS OF DECEMBER 10, 2014 FOURTH SUPPLEMENTAL INDENTURE, dated as of February 22, 2023 (the “Supplemental Indenture”), to the Base Indenture (defined below) between MEDTRONIC, INC., a

Annex I to Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022.

ANNEX I TO AMENDMENT NO. 4 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF DECEMBER 12, 2022 EXECUTION COPY Conformed for Amendment No. 2 and Extension Agreement dated as of December 12, 2020 and Amendment No. 3 and Extension Agreement dated as of December 13, 2021 Published CUSIP Number: Deal L7000JAA8 Revolver L7000JAB6 AMENDED AND RESTATED CREDIT AGREEMENT ($3,5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 27, 2023 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 27, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022.

EXECUTION COPY AMENDMENT NO. 4 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 12, 2022 AMENDMENT NO. 4 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) among MEDTRONIC GLOBAL HOLDINGS S.C.A., a partnership limited by shares (société en commandite par actions) incorporated under the laws of the Grand-Duchy of Luxembou

Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN – Feb.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

MDT / Medtronic PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01403-medtronicplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Medtronic plc Title of Class of Securities: Common Stock CUSIP Number: G5960L103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rul

OBIO / Orchestra BioMed Holdings Inc / Medtronic plc - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Orchestra BioMed Holdings, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 68572M106 (CUSIP Number) January 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 13, 2022, pursuant to the provisions of Rule 12d2-2 (a).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 28, 2022 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 28, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports second quarter fiscal 2023 financial results Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2023 financial results Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic Global Holdings S.C.A. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic Global Holdings S.C.A. (Exact name of registrant as specified in its charter) Luxembourg 98-1202865 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Ident

Consent of Thomas L. Osteraas, Principal Legal Counsel, Corporate & Securities of Medtronic, Inc. (included in Exhibit 5.4).

Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com September 21, 2022 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic Global Holdings S.C.A. Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic Global Holdings S.C.A, an entity organized under the laws of Luxembourg (?Me

DATED SEPTEMBER 21, 2022 MEDTRONIC GLOBAL HOLDINGS S.C.A. PAYING AGENT ELAVON FINANCIAL SERVICES DAC TRANSFER AGENT U.S. BANK TRUST COMPANY, N.A. U.S. BANK TRUST COMPANY, N.A. - AND - COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT

Exhibit 4.3 DATED SEPTEMBER 21, 2022 ISSUER MEDTRONIC GLOBAL HOLDINGS S.C.A. PAYING AGENT ELAVON FINANCIAL SERVICES DAC TRANSFER AGENT U.S. BANK TRUST COMPANY, N.A. REGISTRAR U.S. BANK TRUST COMPANY, N.A. - AND - TRUSTEE COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT relating to certain Notes issued under a supplemental indenture dated September 21, 2022 CONTENTS CLAUSE PAGE 1.

Underwriting Agreement, dated as of September 15, 2022, among Medtronic Global Holdings S.C.A., Medtronic plc and Medtronic, Inc., and Barclays Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Limited and HSBC Continental Europe, as representatives of the several underwriters named therein.

Exhibit 1.1 UNDERWRITING AGREEMENT ?3,500,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. 2.625% Senior Notes due 2025 3.000% Senior Notes due 2028 3.125% Senior Notes due 2031 3.375% Senior Notes due 2034 Underwriting Agreement September 15, 2022 Barclays Bank PLC BofA Securities Europe SA Citigroup Global Markets Limited HSBC Continental Europe Academy Securities, Inc. R. Seelaus & Co., LLC Samuel A. R

Opinion of DLA Piper, Luxembourg counsel to Medtronic Global Holdings S.C.A.

Exhibit 5.3 DLA Piper Luxembourg 37A, Avenue John F. Kennedy L-1855 Luxembourg T +352 26 29 04 2052 F +352 26 29 04 3000 W www.dlapiper.com Medtronic Global Holdings S.C.A. 40 avenue Monterey L-2163 Luxembourg Grand Duchy of Luxembourg Our reference LM/CN LU/410009/33 (?Addressee? or ?you?) September 21, 2022 By Courier and E-mail Dear Sir Dear Madam 1. ROLE OF DLA PIPER LUXEMBOURG 1.1 DLA Piper L

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numb

Fifth Supplemental Indenture, dated as of September 21, 2022, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes).

Exhibit 4.1 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee, and ELAVON FINANCIAL SERVICES DAC, as Paying Agent FIFTH SUPPLEMENTAL INDENTURE DATED AS OF SEPTEMBER 21, 2022 TO INDENTURE DATED AS OF MARCH 28, 2017 Relating to ?500,000,00

Calculation of Filing Fee Tables (Form Type) MEDTRONIC GLOBAL HOLDINGS S.C.A. MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: MEDTRONIC GLOBAL HOLDINGS S.

€3,500,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. €500,000,000 2.625% Senior Notes due 2025 €1,000,000,000 3.000% Senior Notes due 2028 €1,000,000,000 3.125% Senior Notes due 2031 €1,000,000,000 3.375% Senior Notes due 2034 Fully and Unconditionally Gu

Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-236739 PROSPECTUS SUPPLEMENT (To Prospectus dated February 28, 2020) ?3,500,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. ?500,000,000 2.625% Senior Notes due 2025 ?1,000,000,000 3.000% Senior Notes due 2028 ?1,000,000,000 3.125% Senior Notes due 2031 ?1,000,000,000 3.375% Senior Notes due 2034 Fully and Unconditionally Guaran

Medtronic Global Holdings S.C.A. Pricing Term Sheet September 15, 2022 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: September 15, 2022 Settlement Date*: September 21, 2022 Denominations: €100,000

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-236739 September 15, 2022 Medtronic Global Holdings S.C.A. Pricing Term Sheet September 15, 2022 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: September 15, 2022 Settlement Date*: September 21, 2022 Denominations: ?100,000 x ?1,000 Listing: Issuer intends to apply

Subject to Completion, dated September 15, 2022

Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-236739 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not

Letter Agreement by and between Medtronic, Inc. and Ivan K. Fong dated November 19, 2021

Office of Chairman and Chief Executive Officer Medtronic, Inc. 710 Medtronic Parkway, LC210 Minneapolis, MN 55432-5604 USA Tel: 1.763.514.4000 www.medtronic.com November 19, 2021 Dear Ivan, I am pleased to provide you with this offer of employment at Medtronic (the Company). Your valuable experience and expertise will help shape our business and improve the lives of patients. Building the right te

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports first quarter fiscal 2023 financial results Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2023 financial results Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the app

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the app

DEF 14A 1 d382106ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

Medtronic Board appoints Lidia Fonseca as a new director

CONTACTS Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Lidia Fonseca as a new director DUBLIN ? June 27, 2022 ? Medtronic plc (NYSE:MDT) today announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022.

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ☐ Transition report pursuant to Sectio

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ? Medtronic plc

Description of Registrant's Securities

Exhibit 4.25 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the ?Ordinary Shares?), of Medtronic plc, a company incorporated under the laws of Ireland (?Medtronic? or ?Medtronic plc?), and (ii) the 0.000% Senior Notes due 2022, 0.375% Senior Notes due 2023, 0.000% Senior Notes due 2023, 0.25% Senior Notes due 2025, 0.000% Senior Notes due 2025, 1.125%

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 29, 2022 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Conflict Minerals Report of the Company

EX-1.01 2 exhibit101-2021conflictmin.htm EX-1.01 Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2021 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2021 to December 31, 2021 (the “Reporting Period”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of principal executive of

Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN ?

Medtronic and DaVita announce new kidney health technology company Companies join forces to accelerate kidney care device innovation and improve patient outcomes

FOR IMMEDIATE RELEASE Medtronic and DaVita announce new kidney health technology company Companies join forces to accelerate kidney care device innovation and improve patient outcomes DUBLIN and DENVER ? May 26, 2022 ? Medtronic plc (NYSE: MDT) and DaVita Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Term Loan Agreement, dated as of May 2, 2022, by and among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic plc, and Mizuho Bank, Ltd., as administrative agent and as lender.

Exhibit 10.01 EXECUTION COPY ?300,000,000,000 TERM LOAN AGREEMENT dated as of May 2, 2022 among MEDTRONIC GLOBAL HOLDINGS S.C.A. as Borrower, and MEDTRONIC, INC. and MEDTRONIC PLC, as Guarantors, THE LENDERS PARTY HERETO, and MIZUHO BANK, LTD., as Administrative Agent TABLE OF CONTENTS Page Article I Definitions 1 Section 1.01. Defined Terms 1 Section 1.02. Terms Generally 15 Section 1.03. Account

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commissi

2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).

2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Section 1.Purpose; Definitions 1.1Purpose The purpose of this 2021 Medtronic plc Long Term Incentive Plan (this ?Plan?) is to give Medtronic plc, an Irish public limited company (the ?Company?) and its Subsidiaries (as defined below) a competitive advantage in attracting, retaining, and motivating officers, employees, directors, and consultants and to pr

Restricted Stock Unit Award Agreement for awards vesting 100% on the third anniversary of the grant date - 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.

Non-Qualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Restricted Stock Unit Award Agreement for awards vesting ratably on the first, second, third, and fourth anniversary of the grant date - 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.6 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.

Medtronic Capital Accumulation Plan Deferral Program (as restated generally effective January 1, 2017) (Conformed through the Amendment generally effective as of January 1, 2022) (incorporated by reference to Exhibit 10.1 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).

MEDTRONIC CAPITAL ACCUMULATION PLAN DEFERRAL PROGRAM (as restated generally effective January 1, 2017) (Conformed through the Amendment generally effective as of January 1, 2022) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT 1 Section 1.

Performance Share Unit Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports third quarter fiscal 2022 financial results

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2022 financial results Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN ? Feb.

MDT / Medtronic PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Medtronic plc Title of Class of Securities: Common Stock CUSIP Number: G5960L103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule

NPCE / Neuropace, Inc. / Medtronic plc - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroPace, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 641288 10 5 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned directors and/or officers of Medtronic plc, an Irish public limited company (the ?Company?), hereby appoints each of Bradley E. Lerman and Martha Ha, acting individually or jointly, as their true and lawful attorney-in-fact and agent, in any and all capacities, with full power of substitution, to do any and all acts and execute any and all doc

As filed with the Securities and Exchange Commission on December 22, 2021.

As filed with the Securities and Exchange Commission on December 22, 2021. Registration No. 333-201737 Registration No. 333-221962 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-201737 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-221962 UNDER THE SECURITIES ACT OF 1933 Me

Power of Attorney

EX-24.1 4 mdts-8pos12222021xex241xpo.htm EX-24.1 Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned directors and/or officers of Medtronic plc, an Irish public limited company (the “Company”), hereby appoints each of Bradley E. Lerman and Martha Ha, acting individually or jointly, as their true and lawful attorney-in-fact and agent, in any and all capacities, with full power of substitution, t

As filed with the Securities and Exchange Commission on December 22, 2021.

As filed with the Securities and Exchange Commission on December 22, 2021. Registration No. 333-201737 Registration No. 333-221962 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-201737 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-221962 UNDER THE SECURITIES ACT OF 1933 Me

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned directors and/or officers of Medtronic plc, an Irish public limited company (the ?Company?), hereby appoints each of Bradley E. Lerman and Martha Ha, acting individually or jointly, as their true and lawful attorney-in-fact and agent, in any and all capacities, with full power of substitution, to do any and all acts and execute any and all doc

As filed with the Securities and Exchange Commission on December 22, 2021

As filed with the Securities and Exchange Commission on December 22, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

-end-

EX-99.1 2 exhibit991-pressrelease121.htm EX-99.1 NEWS RELEASE Contacts: Pamela Reese Ryan Weispfenning Public Relations Investor Relations +1-818-576-3398 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Diabetes receives FDA warning letter DUBLIN ― December 15, 2021 ― Medtronic plc (NYSE:MDT) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) on December

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

Amendment No. 3 and Extension Agreement to the Amended and Restated Credit Agreement, dated as of December 13, 2021, by and among Medtronic Global Holdings S.C.A., certain subsidiaries of Medtronic plc from time to time party thereto, Medtronic, Inc., Medtronic plc, the lenders from time to time party thereto and Bank of America N.A., as administrative agent.

EX-10.01 2 exhibit1001-amendmentno3an.htm EX-10.01 EXECUTION COPY AMENDMENT NO. 3 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 13, 2021 AMENDMENT NO. 3 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) among MEDTRONIC GLOBAL HOLDINGS S.C.A., a partnership limited by shares (société en commandite par actions) incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 29, 2021 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 29, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports second quarter fiscal 2022 financial results Company continued to launch new products, win share, and deliver strong earnings growth; market procedure volumes impacted by COVID-19 resurgence

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2022 financial results Company continued to launch new products, win share, and deliver strong earnings growth; market procedure volumes impacted by COVID-19 resurgence DUBLIN ? Nov.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ☑ Filed by the Registrant ☐ Filed by a Party other than the Regist

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 Medtronic Publ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ☑ Filed by the Registrant ☐ Filed by a Party other than the Regist

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 1

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

MEDTRONIC REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product Launches

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product Launches DUBLIN ? Aug.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS; ANNOUNCES 9% DIVIDEND INCREASE

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS; ANNOUNCES 9% DIVIDEND INCREASE ?Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic ?Q4 GAAP Diluted EPS of $1.00; Q4 Non-GAAP Diluted EPS of $1.50 ?Quarte

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 30, 2021 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 30, 2021. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ? Medtronic plc

Description of Registrant's Securities

Exhibit 4.25 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the ?Ordinary Shares?), of Medtronic plc, a company incorporated under the laws of Ireland (?Medtronic? or ?Medtronic plc?), and (ii) the 0.000% Senior Notes due 2022, 0.375% Senior Notes due 2023, 0.000% Senior Notes due 2023, 0.25% Senior Notes due 2025, 0.000% Senior Notes due 2025, 1.125%

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of BRADLEY E.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Medtronic Public Limited Company (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commiss

MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS; ANNOUNCES 9% DIVIDEND INCREASE

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS; ANNOUNCES 9% DIVIDEND INCREASE ?Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic ?Q4 GAAP Diluted EPS of $1.00; Q4 Non-GAAP Diluted EPS of $1.50 ?Quarte

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic Public Limited Company Conflict Minerals Report For the Year Ended December 31, 2020 Overview This Conflict Minerals Report (this ?Report?) of Medtronic Public Limited Company (?Medtronic,? the ?Company,? ?we,? ?us,? and ?our?) has been prepared by us on a consolidated basis for the reporting period from January 1, 2020 to December 31, 2020 (the ?Reporting Period?) pursuant

- SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic Public Limited Company (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of pri

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroPace, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (CUSIP Number)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroPace, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 641288 10 5 (CUSIP Number) April 21, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

JOINT FILING AGREEMENT

EXHIBIT 1 JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13G to which this joint filing agreement is attached, along with any amendments thereto that may be required, and have duly executed this joint filing agreement as of the date set forth below.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commi

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the stated securities from listing and registration on the Exchange at the opening of business on March 19, 2021, pursuant to the provisions of Rule 12d2-2 (a).

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 29, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

MEDTRONIC REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS •Q3 Revenue of $7.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 Medtronic Public Limited Company (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Co

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Co

MEDTRONIC ANNOUNCES VOLUNTARY RECALL OF UNUSED VALIANT NAVION™ THORACIC STENT GRAFT SYSTEM

NEWS RELEASE Contacts: Ben Petok Ryan Weispfenning Public Relations Investor Relations +1-612-297-0501 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC ANNOUNCES VOLUNTARY RECALL OF UNUSED VALIANT NAVION? THORACIC STENT GRAFT SYSTEM DUBLIN ? February 17, 2021 ? Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion? thoracic stent graft system and informed physicians to immediately cease use of the device until further notice.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Medtronic plc Title of Class of Securities: Common Stock CUSIP Number: G5960L103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Medtronic plc (Name of Issuer) Common Stock (Title of Class of Securities) G5960L103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Com

SEAN SALMON NAMED EVP & PRESIDENT CARDIOVASCULAR PORTFOLIO; CONTINUES AS EVP & PRESIDENT DIABETES OPERATING UNIT

NEWS RELEASE Contacts: Marguerite Copel Ryan Weispfenning Public Relations Investor Relations +1-203-214-8243 +1-763-505-4626 FOR IMMEDIATE RELEASE SEAN SALMON NAMED EVP & PRESIDENT CARDIOVASCULAR PORTFOLIO; CONTINUES AS EVP & PRESIDENT DIABETES OPERATING UNIT DUBLIN – December 14, 2020 – Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1.

- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 30, 2020 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Form of Performance Share Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).

These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by your company, not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments.

Medtronic Capital Accumulation Plan Deferral Program (restated November 6, 2020) (incorporated by reference to Exhibit 10.4 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).

MEDTRONIC CAPITAL ACCUMULATION PLAN DEFERRAL PROGRAM (as restated generally effective January 1, 2017) (Conformed through the Amendment adopted November 6, 2020) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT 1 Section 1.

Amended and Restated Covidien Supplemental Savings and Retirement Plan (restated November 6, 2020) (incorporated by reference to Exhibit 10.2 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).

COVIDIEN SUPPLEMENTAL SAVINGS AND RETIREMENT PLAN Amended and Restated Adopted by Tyco Healthcare Group LP (renamed as Covidien LP on September 28, 2012) Effective as of January 1, 2010 (Conformed through the Amendment adopted November 6, 2020) TABLE OF CONTENTS ARTICLE I Purpose 1 1.

Medtronic Non-Qualified Retirement Plan Supplemental (restated November 6, 2020, and formerly known as the Supplemental Executive Retirement Plan) (incorporated by reference to Exhibit 10.3 to Medtronic plc’s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).

MEDTRONIC NONQUALIFIED RETIREMENT PLAN SUPPLEMENT (as restated generally effective May 1,2017) (Conformed through the Amendment adopted November 6, 2020) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT 13 Section 1.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2020 Medtronic Public Limited Company (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Co

MEDTRONIC REPORTS SECOND QUARTER FISCAL 2021 FINANCIAL RESULTS

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS SECOND QUARTER FISCAL 2021 FINANCIAL RESULTS •Q2 Revenue of $7.

- 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2020 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

- 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2020 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 26, 2020, pursuant to the provisions of Rule 12d2-2 (a).

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2))

- DEFR14A

DEFR14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Comm

Opinion of DLA Piper, Luxembourg counsel to Medtronic Global Holdings S.C.A.

EX-5.3 Exhibit 5.3 DLA Piper Luxembourg 37A, Avenue John F. Kennedy L-1855 Luxembourg T +352 26 29 04 2052 F +352 26 29 04 3000 W www.dlapiper.com Our reference Medtronic Global Holdings S.C.A. 40 avenue Monterey L-2163 Luxembourg Grand Duchy of Luxembourg LM/CN LU/410009/33 (“Addressee” or “you”) September 29, 2020 By Courier and E-mail Dear Sir Dear Madam 1.   ROLE OF DLA PIPER LUXEMBOURG 1.1  D